Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

Celestia Higano, MD
Published: Thursday, Aug 31, 2017



Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Approximately one-quarter of patients with metastatic prostate cancer have DNA-damaged alterations, states Higano. PARP inhibitors are a different treatment paradigm for prostate cancer that have shown to be effective in this patient population.
 


Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Approximately one-quarter of patients with metastatic prostate cancer have DNA-damaged alterations, states Higano. PARP inhibitors are a different treatment paradigm for prostate cancer that have shown to be effective in this patient population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x